But while it is true that the price of this miracle treatment is eye-poppingly higher in the United States than it is in India (or just about anywhere else in the world), it's reductive to say that this is simply the end result of Big Pharma owning American politicians. There are sev...
In Japan, 1.5–2 million people are chronically infected with hepatitis C virus (HCV) infection. New direct-acting antiviral agents (DAA) offer an unprecedented opportunity to cure HCV. While the price of HCV treatment decreased recently in most countries, it remains one of the highest in Japan...
While the price of HCV treatment decreased recently in most countries, it remains one of the highest in Japan. Our objective was to evaluate the cost-effectiveness of HCV treatment in patients of different age groups and to estimate the price at which DAAs become cost-saving in Japan. A ...
The prognosis for a person with hepatitis C is variable, depending upon when the infection is diagnosed and when treatment is begun. Approximately 15%-25% of infected patients cure themselves without the need for treatment. Those who do not spontaneously cure the infection become chronically (persi...
Despite the remarkable improvements in pharmacologic treatment efficacy for hepatitis C (HCV) reported in published clinical trials, published research suggests that, in "real-world" patient care, these medical outcomes may be difficult to achieve. This review was undertaken to summarize recent experienc...
Hepatocyte proliferation and hepatitis C virus kinetics during treatment. In a recent study of modeling hepatitis C virus (HCV) kinetics under therapy with peginterferon-a+ribavirin, Snoeck et al., in "A Comprehensive Hepatitis C... Dahari H,Rong L,Layden TJ,... - Clinical Pharmacology and ...
Hepatitis C treatment with the newest medications and most modern technologies by Dr. Peter J. Ruane
In 2014, sofosbuvir generated US$10.3 billion in sales. While the high cost of treatment has come under scrutiny, Gilead's executives said "price is the wrong discussion … value should be the subject". Drug companies appear well aware such innovative treatments for hepatitis C will be well s...
"These new oral treatments provide better clinical results with fewer side effects for all patients, but at the current price, are only good value for those who needtreatmentthe most - patients with advancedliver diseaseor those who failed prior therapy," Linas said. "With lower costs, it wou...
Interferon plus amantadine versus interferon alone in the treatment of na¨ive patients with chronic hepatitis C: a UK multicenter study. J Hepatol 2001;... Simona,Caronia,and,... - 《Journal of Hepatology》 被引量: 280发表: 2001年 Quantitation of hepatitis B virus (HBV) covalently closed ...